|
Abstract To explore the success effect of prevention of mother to child transmission (PMTCT) of passive immunotherapy combined with antiviral therapy for treating pregnant women with hepatitis B virus (HBV) infection. Methods: A total of 138 pregnant women with HB infection were selected and randomly divided into two groups (69 cases in each group) according to the number table method from January 2019 to January 2020. The women in group A were treated by tenofovir, and the women in group B were treated by tenofovir combined with immune globulin of HBV. The levels of HBV-DNA, gamma-glutamyl transferase (GGT), alanine transaminase (ALT), and aspartate transaminase (AST) of the women before and after treatment were measured. The ALT normalization rate, the HBV DNA negative rate, the neonatal HBsAg positive rate, the HBsAb positive rate, the HBV DNA positive rate, the success rate PMTCT, the neonatal complications situation of the women were statistics analyzed and were compared between the two groups. After treatment, the serum AST and GGT levels of the women in the two groups had decreased significantly, and which of the women in group B were significantly lower than those of the women in group A (P<0.05). The serum ALT level and HBV-DNA load of the women in group B were significantly lower than those of the women in group A. The ALT normalization rate (91.3%), the HBV-DNA negative rate (87.0%), the PMTCT rate (97.1%), and the HBsAb positive rate (97.1%) of the women in group B were significantly higher than those of the women in group A, and the HBsAg positive rate (0), the HBV-DNA positive rate (1.5%), the neonatal IgA, IgM, IgG levels, and the complications rate (2.9%) of the women in group B were significantly lower than those of the women in group A (P<0.05). Conclusion: Passive immunotherapy combined with antiviral therapy for treating pregnant women with HBV infection can reduce their serum HBV-DNA level, improve their liver function and immune function, and increase the rate of ALT recurrence and the HBV DNA negative conversion ratio of the women, and can improve the neonatal immunity and reduce the risk of neonatal complications, and which has better efficacy of PMTCT.
|
|
|
|
|
|
